Key statistics
As of last trade Aligos Therapeutics Inc (5WK:DUS) traded at 0.476, 0.00% above its 52-week low of 0.476, set on Aug 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.476 |
Low | 0.476 |
Bid | -- |
Offer | -- |
Previous close | 11.90 |
Average volume | -- |
---|---|
Shares outstanding | 3.20m |
Free float | 2.46m |
P/E (TTM) | -- |
Market cap | 23.40m USD |
EPS (TTM) | -25.99 USD |
Data delayed at least 15 minutes, as of Aug 16 2024 18:32 BST.
More ▼
Announcements
- Aligos Therapeutics Appoints David Perry as Vice President of Business Development
- Aligos Therapeutics to Present at Investor Conferences in October
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
- Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Announces Reverse Stock Split
- Aligos Therapeutics Strengthens Board with Two New Independent Directors
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
- Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
More ▼